NASDAQ
28.51USD
-0.92 (-3.13%)
We have scored 15 news catalysts on Adaptive Biotechnologies Corporation (ADPT) over the past 12 months. The biggest single-day move next to one of them came Dec 6, 2025, when ADPT closed −15.5%: “Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting”. Coverage across the window leans positive (average ticker sentiment +0.31). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.6B
P/E
—
EPS
—
Beta
2.10
52W range
12-29.96
Day range
28.07–29.52
Open
29.00
Prev close
29.43
Volume
2.6M
Avg volume
2.7M
Dividend
0.00
IPO
2019-06-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Adaptive Biotechnologies Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ADPT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
